PROLOR Biotech Announces Participation in Leerink Swann Hot Topics in Therapeutics Conference

PROLOR Biotech, Inc., a clinical stage biopharmaceutical company, has been selected to participate in a panel on Emerging Platforms at the Leerink Swann Hot Topics in Therapeutics: Roundtable Conference. The company's CEO, Dr. Abraham Havron, will give a corporate presentation at the conference, which will be held at the Roosevelt Hotel in New York City. The presentation will focus on PROLOR's unique technology, CTP, and its application to develop longer-acting versions of already approved therapeutic proteins.

Key Takeaways:

• PROLOR Biotech has been selected to participate in the Leerink Swann Hot Topics in Therapeutics: Roundtable Conference due to its innovative approach to developing longer-acting therapeutic proteins.
• The company's CEO, Dr. Abraham Havron, will give a corporate presentation at the conference, highlighting its patented CTP technology and its applications in human growth hormone, Factor IX, Factor VII, interferon beta, erythropoietin, anti-obesity peptide, and agents for atherosclerosis and rheumatoid arthritis.
• PROLOR Biotech is developing long-acting versions of already approved therapeutic proteins through its proprietary CTP technology, which has the potential to generate significant revenue.
• The company has already initiated Phase II clinical development for its long-acting human growth hormone and is in preclinical development for other treatments, including Factor IX, Factor VII, interferon beta, and erythropoietin.
• The Leerink Swann Roundtable Conference series spotlights the most promising healthcare and life sciences sectors and companies, and PROLOR Biotech has been selected for its innovative approach and potential for growth.

Statistics:

• The Leerink Swann Roundtable Conference series features the most promising healthcare and life sciences sectors and companies, with a focus on emerging platforms and innovative approaches.
• PROLOR Biotech's participation in the conference is a testament to its innovative approach to developing longer-acting therapeutic proteins.
• The company's CTP technology has the potential to generate significant revenue through the development of longer-acting versions of already approved therapeutic proteins.
• PROLOR Biotech has initiated Phase II clinical development for its long-acting human growth hormone and is in preclinical development for other treatments.

Sources:

• "PROLOR Biotech Announces Participation in Leerink Swann Hot Topics in Therapeutics Conference" (PRNewswire, February 7, 2011)
• "About PROLOR Biotech" (PROLOR Biotech website, February 2011)
• "Leerink Swann Hot Topics in Therapeutics: Roundtable Conference" (Leerink Swann website, February 2011)
• "MEDACorp" (MEDACorp website, February 2011)